Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 139 matching drugs for PRDX1 — including drugs targeting any of its 35 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
disulfiram, copper, alkylating agents PRDX1 Direct 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR1 SSL via FGFR1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR1 SSL via FGFR1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR1 SSL via FGFR1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FYN SSL via FYN 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR1 SSL via FGFR1 3
pembrolizumab, belzutifan, lenvatinib FGFR1 SSL via FGFR1 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR1 SSL via FGFR1 2
bbi-355, erlotinib, futibatinib FGFR1 SSL via FGFR1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FYN SSL via FYN 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib FGFR1 SSL via FGFR1 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR1 SSL via FGFR1 2
lenvatinib, pembrolizumab FGFR1 SSL via FGFR1 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR1 SSL via FGFR1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR1 SSL via FGFR1 2
nintedanib FGFR1 SSL via FGFR1 yes 2
nintedanib, pembrolizumab FGFR1 SSL via FGFR1 2
pembrolizumab, lenvatinib FGFR1 SSL via FGFR1 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR1 SSL via FGFR1 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR1 SSL via FGFR1 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FGFR1 SSL via FGFR1 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib FGFR1 SSL via FGFR1 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
regorafenib, laboratory biomarker analysis FGFR1 SSL via FGFR1 2
sorafenib, administered orally, ct/mri FGFR1 SSL via FGFR1 2
afatinib, dasatinib, palbociclib, everolimus, olaparib ABL1 SSL via ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FYN SSL via FYN 1
atezolizumab, tivozanib FGFR1 SSL via FGFR1 1
bevacizumab, dasatinib, placebo ABL1 SSL via ABL1 1
bevacizumab, dasatinib, placebo FYN SSL via FYN 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging FGFR1 SSL via FGFR1 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography FGFR1 SSL via FGFR1 1
bosutinib ABL1 SSL via ABL1 yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FGFR1 SSL via FGFR1 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin HSPA5 SSL via HSPA5 1
cisplatin, pemetrexed disodium, sorafenib FGFR1 SSL via FGFR1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride ABL1 SSL via ABL1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FYN SSL via FYN 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method ABL1 SSL via ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FYN SSL via FYN 1
dasatinib, laboratory biomarker analysis, physiologic testing ABL1 SSL via ABL1 1
dasatinib, laboratory biomarker analysis, physiologic testing FYN SSL via FYN 1
dasatinib, mfolfox6 ABL1 SSL via ABL1 1
dasatinib, mfolfox6 FYN SSL via FYN 1
dasatinib, pharmacological study ABL1 SSL via ABL1 1
dasatinib, pharmacological study FYN SSL via FYN 1
dasatinib, temozolomide, placebo, radiation therapy ABL1 SSL via ABL1 1
dasatinib, temozolomide, placebo, radiation therapy FYN SSL via FYN 1
dimethyl fumarate, temozolomide, radiation therapy KEAP1 SSL via KEAP1 1
disulfiram, copper, alkylating agents HSPA5 SSL via HSPA5 1
endoscopic variceal ligation, carvedilol HIF1A SSL via HIF1A 1
erdafitinib FGFR1 SSL via FGFR1 yes 1
everolimus, sorafenib FGFR1 SSL via FGFR1 1
gemcitabine, erlotinib, sorafenib FGFR1 SSL via FGFR1 1
gemcitabine, oxaliplatin, imatinib ABL1 SSL via ABL1 1
gemcitabine, placebo, sorafenib FGFR1 SSL via FGFR1 1
gemcitabine, sorafenib, radiotherapy FGFR1 SSL via FGFR1 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff FGFR1 SSL via FGFR1 1
h101, tislelizumab, lenvatinib FGFR1 SSL via FGFR1 1
imatinib, irinotecan, carboplatin ABL1 SSL via ABL1 1
intestinal, multivisceral or modified multivisceral transplantation, alemtuzumab, tacrolimus, sirolimus FKBP1A SSL via FKBP1A 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil FGFR1 SSL via FGFR1 1
lenvatinib, bevacizumab FGFR1 SSL via FGFR1 1
medical cannabis SOD1 SSL via SOD1 1
mycophenolate mofetil, tacrolimus, post-transplant cyclophosphamide, total body irradiation, hematopoietic cell transplant, jsp191, cyclophosphamide, fludarabine FKBP1A SSL via FKBP1A 1
nabiximols, temozolomide, nabiximols-matched placebo SOD1 SSL via SOD1 1
oxaliplatin, sorafenib FGFR1 SSL via FGFR1 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) FGFR1 SSL via FGFR1 1
pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) FKBP1A SSL via FKBP1A 1
patupilone TUBA1B SSL via TUBA1B 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel FGFR1 SSL via FGFR1 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel FGFR1 SSL via FGFR1 1
pemigatinib FGFR1 SSL via FGFR1 yes 1
ponatinib ABL1 SSL via ABL1 yes 1
ponatinib FGFR1 SSL via FGFR1 1
radiation therapy, temozolomide, sorafenib FGFR1 SSL via FGFR1 1
regorafenib, lomustine ABL1 SSL via ABL1 1
regorafenib, lomustine FGFR1 SSL via FGFR1 1
regorafenib, nivolumab, capeox, folfox regimen ABL1 SSL via ABL1 1
regorafenib, nivolumab, capeox, folfox regimen FGFR1 SSL via FGFR1 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil ABL1 SSL via ABL1 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil FGFR1 SSL via FGFR1 1
regorafenib, temozolomide ABL1 SSL via ABL1 1
regorafenib, temozolomide FGFR1 SSL via FGFR1 1
selpercatinib FGFR1 SSL via FGFR1 1
serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome FGFR1 SSL via FGFR1 1
sorafenib FGFR1 SSL via FGFR1 1
sorafenib, erlotinb FGFR1 SSL via FGFR1 1
sorafenib, rad001 FGFR1 SSL via FGFR1 1
sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide FGFR1 SSL via FGFR1 1
tace, lenvatinib, combined with tislelizumab group FGFR1 SSL via FGFR1 1
tace, tislelizumab, lenvatinib FGFR1 SSL via FGFR1 1
tacrolimus modified release (mr), tacrolimus FKBP1A SSL via FKBP1A 1
tacrolimus, methotrexate, sirolimus FKBP1A SSL via FKBP1A 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.